UBS ASSET MANAGEMENT AMERICAS LLC - CTI BIOPHARMA CORP ownership

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS LLC ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q2 2023$389,3400.0%92,7000.0%0.00%
Q1 2023$389,340
-14.4%
92,700
+22.5%
0.00%
Q4 2022$454,95775,7000.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 3,904,400$3,355,0002.31%
BVF INC/IL 6,929,690$5,955,0000.65%
CAXTON CORP 324,452$279,0000.32%
NEA Management Company, LLC 3,750,000$3,222,0000.23%
Orbimed Advisors 5,000,000$4,297,0000.07%
Fosun International Ltd 459,274$390,0000.03%
Paloma Partners Management Co 229,800$197,0000.00%
OXFORD ASSET MANAGEMENT LLP 127,602$110,0000.00%
LMR Partners LLP 54,931$47,0000.00%
Tower Research Capital LLC (TRC) 17,495$15,0000.00%
View complete list of CTI BIOPHARMA CORP shareholders